Loading...
Docoh

Prestige Consumer Healthcare (PBH)

Prestige Consumer Healthcare markets, sells, manufactures and distributes consumer healthcare products to retail outlets throughout the U.S. and Canada, Australia, and in certain other international markets. The Company's diverse portfolio of brands include Monistat® and Summer's Eve® women's health products, BC® and Goody's® pain relievers, Clear Eyes® eye care products, DenTek® specialty oral care products, Dramamine® motion sickness treatments, Fleet® enemas and glycerin suppositories, Chloraseptic® and Luden's® sore throat treatments and drops, Compound W® wart treatments, Little Remedies® pediatric over-the-counter products, Boudreaux's Butt Paste® diaper rash ointments, Nix® lice treatment, Debrox® earwax remover, Gaviscon® antacid in Canada, and Hydralyte® rehydration products and the Fess® line of nasal and sinus care products in Australia.

Company profile

Ticker
PBH
Exchange
CEO
Ronald M. Lombardi
Employees
Location
Fiscal year end
Former names
Prestige Brands Holdings, Inc.
SEC CIK
Subsidiaries
of Prestige Consumer Healthcare Inc. • Blacksmith Brands, Inc. • C.B. Fleet Company, Incorporated • C.B. Fleet Investment Corporation • C.B. Fleet International LLC • C.B. Fleet International(s) Pte. Ltd • Care Acquisition Company Pty Limited • Care Pharmaceuticals Pty Limited • Cellegy Australia • Clear Eyes Pharma Limited ...
IRS number
201297589

PBH stock data

Calendar

4 Aug 22
28 Sep 22
31 Mar 23
Quarter (USD) Jun 22 Mar 22 Dec 21 Sep 21
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD) Mar 22 Mar 21 Mar 20 Mar 19
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Cash burn rate (est.) Burn method: Change in cash Burn method: Operating income Burn method: FCF (opex + capex)
Last Q Avg 4Q Last Q Avg 4Q Last Q Avg 4Q
Cash on hand (at last report) 35.87M 35.87M 35.87M 35.87M 35.87M 35.87M
Cash burn (monthly) (no burn) 10.65M (no burn) (no burn) (no burn) (no burn)
Cash used (since last report) n/a 31.43M n/a n/a n/a n/a
Cash remaining n/a 4.44M n/a n/a n/a n/a
Runway (months of cash) n/a 0.4 n/a n/a n/a n/a

Beta Read what these cash burn values mean

Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
2 Aug 22 John E Byom Common Stock, par value $0.01 per share Grant Acquire A No No 0 2,495 0 48,003
2 Aug 22 Clark Celeste A. Common Stock, par value $0.01 per share Grant Acquire A No No 0 2,495 0 6,939
2 Aug 22 Ricciardi Natale S Common Stock, par value $0.01 per share Grant Acquire A No No 0 2,495 0 24,803
2 Aug 22 Coughlin Christopher J Common Stock, par value $0.01 per share Grant Acquire A No No 0 2,495 0 13,218
2 Aug 22 Zier Dawn M. Common Stock, par value $0.01 per share Grant Acquire A No No 0 2,495 0 9,942
13F holders Current Prev Q Change
Total holders 276 279 -1.1%
Opened positions 33 43 -23.3%
Closed positions 36 29 +24.1%
Increased positions 98 116 -15.5%
Reduced positions 116 84 +38.1%
13F shares Current Prev Q Change
Total value 9.85B 2.63B +274.6%
Total shares 50.36M 49.62M +1.5%
Total puts 0 0
Total calls 4.3K 4.2K +2.4%
Total put/call ratio
Largest owners Shares Value Change
BLK Blackrock 9.05M $532.27M -0.7%
Vanguard 5.61M $330.16M +1.0%
Dimensional Fund Advisors 3.48M $204.56M +0.9%
STT State Street 1.92M $112.98M +4.9%
MCQEF Macquarie 1.89M $110.98M +4.4%
FMR 1.33M $78.35M -32.9%
Massachusetts Financial Services 1.28M $75.21M -0.2%
IVZ Invesco 1.03M $60.31M +60.7%
Allspring Global Investments 1.01M $59.1M -9.1%
LSV Asset Management 909.77K $53.5M -3.5%
Largest transactions Shares Bought/sold Change
Ariel Investments 760.15K +760.15K NEW
Ophir Asset Management Pty 722.14K +722.14K NEW
FMR 1.33M -652.28K -32.9%
MS Morgan Stanley 709.7K +448.09K +171.3%
Parametric Portfolio Associates 0 -431.12K EXIT
IVZ Invesco 1.03M +387.37K +60.7%
MNGPF Man 0 -277.96K EXIT
AMP Ameriprise Financial 482.02K +253.88K +111.3%
GS Goldman Sachs 609.58K -195.47K -24.3%
Leeward Investments, LLC - MA 555.3K +172.21K +45.0%

Financial report summary

?
Management Discussion
  • Total revenues for the three months ended June 30, 2022 were $277.1 million, an increase of $7.9 million, or 2.9%, versus the three months ended June 30, 2021.
  • Revenues for the North American OTC Healthcare segment increased $0.1 million, or 0.1%, during the three months ended June 30, 2022 versus the three months ended June 30, 2021. Revenues in the three months ended June 30, 2022 were driven by continued strong performance across many of our key brands but compared to the three months ended June 30, 2021, which experienced significantly increased demand for certain brands, categories and channels that had previously been impacted by the COVID-19 virus, most notably motion sickness. The three months ended June 30, 2022 also benefited from the newly acquired brands, as part of the Akorn acquisition.
  • Revenues for the International OTC Healthcare segment increased $7.8 million, or 28.9%, during the three months ended June 30, 2022 versus the three months ended June 30, 2021. The $7.8 million increase was mainly attributable to increased sales in our Australian subsidiary, primarily related to an increase in sales of Hydralyte (included in the Gastrointestinal category) as a result of easing COVID-19 restrictions, as well as an increase in consumer illnesses.

Content analysis

?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. sophomore Good
New words: duration, exacerbated, feedback, geopolitical, inflationary, instability, invasion, layer, led, modification, motion, multiple, notably, objective, partially, plant, program, purpose, recognition, restructuring, Russian, single, Targeted, troubled, Ukraine, uncertainty, Vintage
Removed: amendment, analyze, annum, appointed, base, begun, Borrower, care, close, Cold, Cough, counterparty, dealing, decline, deferred, derivative, Dermatological, distributed, Ear, employee, end, exposure, Eye, flexibility, floor, home, hygiene, incurred, instance, instrument, limit, manufacture, member, NaN, obligation, Oral, organization, outbreak, pay, positively, realized, refinance, reflected, remained, sheet, Simplifying, spread, stable, strain, substantial, sufficient, temporary, travel, treat, usage, Women